uploads/2019/03/medic-563423_1280-1.jpg

What Analysts Recommend for Pfizer and Mylan in March

By

Updated

Stock price movements

On February 28, Pfizer (PFE) closed at $43.35, 0.98% higher than its previous closing price, 26.31% higher than its 52-week low of $34.32, and 6.71% below its 52-week high of $46.47. Its market capitalization was $254.68 billion, and its trailing-12-month and forward PE ratios were 23.36x and 14.17x, respectively.

Since its fourth-quarter earnings release on January 29, Pfizer stock has risen 10.61% from $39.19 on January 28 to $43.35 on February 28. In the fourth quarter, the company managed to beat its consensus revenue estimate and consensus EPS estimate by $80 million and $0.01, respectively.

Article continues below advertisement

On February 28, Mylan (MYL) closed at $26.39, 1.46% higher than its previous closing price, 1.50% higher than its 52-week low of $26.00, and 40.27% below its 52-week high of $44.18. Its market capitalization was $13.52 billion, and its trailing-12-month and forward PE ratios are 21.32x and 5.24x, respectively.

Since its fourth-quarter earnings release on February 27, Mylan stock has dropped 13.81% from $30.62 on February 26 to $26.39 on February 28. The company surpassed its consensus revenue estimate by $20 million but missed the consensus EPS estimate by $0.05 in the fourth quarter. Mylan is trading at lower trailing PE and forward PE ratios as compared to Pfizer.

Analysts’ recommendations and target price

The 12-month consensus recommendation for Pfizer is a “hold,” while that for Mylan is a “buy.” Two analysts rate Pfizer a “strong buy,” five rate it as a “buy,” seven rate it as a “hold,” while only one analyst rates the company as a “strong sell.” Their 12-month target price is $44.14, 1.82% higher than its last closing price on February 28. The highest, median, and lowest target price estimates for the company are $53, $45, and $35, respectively.

Of the 16 analysts covering Mylan, six recommend a “strong buy,” five recommend a “buy,” and five recommend a “hold.” Their 12-month target price is $37.64, 42.63% higher than its last closing price on February 28. The highest, median, and lowest target price estimates for the company are $47, $37.50, and $25, respectively.

Next, we’ll look at the revenue growth trajectory of Pfizer and Mylan.

Advertisement

More From Market Realist